Delisting, Listing Rule Failure, or Listing Transfer

Vivakor, Inc. (VIVK) - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Vivakor, Inc., a Nevada corporation, on December 16, 2025, covering events occurring on December 10, 2025, and December 11, 2025. The Company's common stock trades on the Nasdaq Capital Market under the symbol "VIVK."

Key Financial Metrics and Capital Activities

The filing details specific capital raising activities rather than standard operating financial metrics such as revenue or net income.

  • October 2025 Offerings: The Company conducted two registered direct offerings in October 2025. On October 24, it issued 10,909,090 shares and 5,000,000 pre-funded warrants at $0.22 per share. On October 30, it issued 10,600,000 shares and 3,566,666 pre-funded warrants at $0.18 per share.
  • Convertible Notes Conversion: Between December 10 and December 15, 2025, the Company converted $507,172.86 of principal from convertible promissory notes (originally issued in June 2025) into 15,427,519 shares of common stock.
  • Net Proceeds from Notes: The original June 2025 note issuance had an aggregate principal of $5,117,647.06, with the Company receiving $4,350,000 net of fees.

Material Changes and Regulatory Status

Nasdaq Delisting Notice (Item 3.01): On December 11, 2025, the Company received a notice from Nasdaq stating it failed to comply with Listing Rule 5635(d) (Shareholder Approval Rule). This rule requires shareholder approval for transactions issuing 20% or more of pre-transaction shares at less than the Minimum Price. The October 2025 offerings collectively exceeded this threshold without prior approval.

  • Immediate Effect: The notice does not immediately delist the stock.
  • Compliance Timeline: The Company has 45 calendar days to submit a plan to regain compliance. If accepted, Nasdaq may grant up to 180 additional days to evidence compliance.
  • Proposed Action: Management plans to seek shareholder approval for the October offerings to regain compliance, though there is no assurance of success.

Outlook, Risks, and Management Commentary

Management acknowledges the risk that the Company may be unable to regain compliance with the Shareholder Approval Rule. Furthermore, even if compliance is regained, there is no assurance the Company can maintain compliance with all Nasdaq listing standards in the future. The conversion of notes into shares was executed pursuant to Section 4(a)(2) of the Securities Act as an exemption for accredited investors.

Investor Verification Checklist

  • Verify the Company's ability to secure shareholder approval for the October 2025 offerings within the 45-day window.
  • Monitor the submission and acceptance of the compliance plan by Nasdaq.
  • Assess the dilution impact of the 15,427,519 shares issued via note conversion and the prior October offerings.
  • Review the Company's cash position and liquidity needs given the reliance on equity and convertible debt financing.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.